Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 40.50
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

4 Apr 2013 07:00

RNS Number : 5304B
Beximco Pharmaceuticals Ltd
04 April 2013
 



April 4, 2013

 

BEXIMCO PHARMACEUTICALS LTD.

 

Change in Directorate

 

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) announces the resignation of Ahsanul Karim and the appointment to the Board of Directors of Faheemul Huq as a Non-Executive Director of the Company.

 

Mr Karim's resignation was accepted by the Board at a Board meeting on 3 April 2013, becoming effective immediately. Mr Karim resigned for personal reasons and the board wishes to thank Mr Karim for the guidance and contribution given while a director of the Company.

 

At the same time the board would like to welcome Mr Huq to the Board. Mr Huq (48) is a Barrister-at-Law in England and Wales, an Advocate to the Supreme Court of Bangladesh and a member of the Bangladesh Supreme Court and Dhaka Bar Associations. He is working at the law firm of Huq and Company where he advises local and international companies on a variety of legal subjects including Corporate law, Corporate Governance and International Arbitration. Mr Huq received LLB (Hon's) from both the University of Dhaka, Bangladesh and Wolverhampton, UK.

 

Mr Huq has been appointed for an initial term of three years, subject to shareholder approval at the Company's next AGM. As one of the independent directors, Mr Huq will take over the role of Chairman of the reconstituted Audit Committee with immediate effect.

 

Additional information about Mr Huq required under Schedule 2 (g) of the AIM Rules:

 

Current Directorships:

AB Bank Limited

Bangladesh Export Import Company Limited

 

There is no further information required to be disclosed under Schedule 2 (g) of the AIM Rules.

 

 

Ends

 

 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan MP, Managing DirectorTel: +880 2 861 9151, ext.20080

 

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 8618220-1, Ext 10140

 

Libertas Capital Corporate Finance (Nomad)

Thilo Hoffmann

Tel: +44 (0)20 7569 9650

 

Daniel Stewart & Company (Broker)

Paul Shackleton

James Thomas

Tel: +44 (0)20 7776 6550

 

FTI Consulting

Simon Conway / Susan Stuart / Victoria Foster-MitchellTel: +44 (0)20 7269 7169

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

 

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADDGDSCUGBGXX
Date   Source Headline
27th Dec 20187:00 amRNSEGM Statement
30th Nov 20187:00 amRNSAGM Notification
30th Nov 20187:00 amRNSEGM Notification
29th Nov 20188:30 amRNSBeximco Pharma wins at Scrip Awards 2018
14th Nov 20187:00 amRNSResults for First Quarter Ended 30 September 2018
7th Nov 20187:00 amRNSResults for the 12 month period ended 30 June 2018
26th Oct 20187:00 amRNSNotification of Preliminary Results and AGM
30th Jul 20187:00 amRNSUS FDA Approves Beximco Pharma's Nadolol Tablets
23rd Jul 20187:00 amRNSCommences export of fourth product to the US
27th Apr 20187:00 amRNS3rd Quarter Results
23rd Apr 20187:00 amRNSCommences Export of Third Product to the US Market
3rd Apr 20187:00 amRNSCompletion of the Acquisition of Nuvista Pharma
30th Jan 20187:00 amRNSHalf Year Results 2017-18
19th Jan 20187:00 amRNSPayment of Cash Dividend
19th Jan 20187:00 amRNSAcquisition of a Majority Stake in Nuvista Pharma
27th Dec 20177:00 amRNSAGM Statement
30th Nov 201710:30 amRNSBeximco Pharma wins at Scrip Awards 2017
23rd Nov 201711:53 amRNSNotice of AGM
14th Nov 20177:00 amRNSResults for First Quarter Ended 30 September 2017
7th Nov 20177:00 amRNSCommencement of Second Product Export to the US
6th Nov 201710:30 amRNSResults for the 12 month period ended 30 June 2017
26th Oct 20177:00 amRNSNotice of Preliminary Results and AGM
6th Oct 20177:00 amRNSSigns a Non-Binding MoU with Nuvista Pharma
2nd Oct 20177:00 amRNSChange of Broker
18th Sep 20177:00 amRNSCommences Export to Canada
25th Jul 20177:00 amRNSFDA approves Beximco Pharma Methocarbamol tablets
28th Apr 20177:00 amRNSFinancial Results for the Third Quarter of 2016-17
27th Jan 20177:00 amRNSHalf year results 2016-17
25th Jan 20177:00 amRNSBeximco Pharma forms JV with BioCare Manufacturing
19th Dec 20167:00 amRNSUS FDA approves Metformin for diabetes control
16th Dec 201610:12 amRNSPayment of Cash Dividend
12th Dec 20161:54 pmRNSStock Dividend Issued and Total Voting Rights
21st Nov 20167:00 amRNSAGM Statement
15th Nov 20167:00 amRNS1st Quarter Results
25th Oct 20167:00 amRNSReceives second product approval from the US FDA
20th Oct 20167:00 amRNSResults for the 18 month period ended 30 June 2016
19th Oct 20167:00 amRNSNotice of AGM
7th Oct 20167:00 amRNSNotification of Preliminary Results and AGM
5th Aug 20167:00 amRNSBeximco Pharma commences export to the US
17th Jun 20167:00 amRNSBeximco Pharma commences export to Kuwait
9th May 20167:00 amRNSFinal Results
6th May 20167:01 amRNSAGM Change and Dividend Update
6th May 20167:00 amRNSChange of Accounting Reference Date
4th May 20167:00 amRNSAmendment to Notification of Preliminary Results
21st Apr 20167:00 amRNSNotification of Preliminary Results and AGM
19th Nov 20157:00 amRNSUS FDA approval to manufacture blood pressure drug
27th Oct 20157:00 amRNS3rd Quarter Results
24th Jul 20157:00 amRNSHalf Yearly Report
13th Jul 201510:53 amRNSPayment of Cash Dividend
26th Jun 20157:00 amRNSStock Dividend Issued and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.